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Certainly final drug products must be “essentially free” of visible particulate contamination and visual inspection 
systems must meet USP 790 criteria. In addition, final drug products must meet USP 788 limits for sub-visible 
particles. It is however important to distinguish final drug product standards from requirements for single-use 
process containers and equipment, even though it is common to claim single-use systems (SUS) “meet USP 
788 requirements”. USP 788 does not describe a method for determination of particulate counts in SUS process 
containers and equipment (1). 
 
Visible particles are “visible” and thus a visual indicator of SUS quality, and consequently sometimes lead to 
visceral reactions and the perception of major or even critical risk to product safety. However, guidance from 
PDA TR66 (2), ASME BPE-2016 (3) and the BPSA (4) published in the last few years provide valuable 
information on assessment of particulate risk in SUS processes. In most situations where SUS are currently 
applied, filtration and purification steps occur downstream, which essentially reduces the risk to zero for transfer 
of particulate contamination from SUS to the final drug product. However, any applications of SUS after final 
filtration (such as in ascetic processes or final filling operations) present significant risk to drug substance or 
drug product. So is risk to final drug product from SUS an essentially a binary situation: Prior to final filtration low 
risk, and after final filtration high risk? 
 
While assembly of SUS is a “clean build” process usually done in ISO 7 classified cleanrooms, incoming 
components and cleanroom processes such as cutting, welding and human assembly are unfortunately not 
particulate-free with current SUS manufacturing technologies. In addition, visual inspection of SUS components 
and assemblies is nowhere near 100% effective at detecting visible particles, especially for large complex 
assemblies or stirred tank reactor systems. Sartorius is currently implementing a “Visible Particle Test” (VPT: 
liquid extraction and microscopy) for process monitoring and continuous improvement efforts. Thus while most 
SUS manufactures strive to minimize particulate contamination, absence of particulates remains a goal but is 
not a currently feasible SUS specification. 
 
Particle contaminants may lie within the interior surfaces of SUS (in the fluid contact path), may be embedded 
within bag films or plastic components, or lie on the exterior surfaces of SUS. Particulates fall into two general 
categories: intrinsic (particles from SUS manufacturing process and component materials) and extrinsic 
(particles from human operators or the environment). Extrinsic particles potentially contain microbiological or 
viral contamination. These classifications of location and particle type lead to different assessments of risk. 
One concern are potential “secondary effects” of particulate contamination. Particle contamination could 
potentially nucleate protein aggregation. Particles embedded in SUS films or plastic components, or on the 
interior surfaces of the SUS assemblies could potentially leach out chemicals or release microbiological or viral 
contamination into the bioprocess fluids. 
In this presentation, the topic of particulate contamination risk is approached holistically and scientifically using 
literature data along with calculations. The goal of the presentation is to gain feedback from end users, and to 
facilitate the discussion between suppliers and end users based upon real rather than perceived risks. 
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